Trials / Terminated
TerminatedNCT02474888
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels could be an interesting tool in the follow-up of ANCA-associated vasculitis patients. All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or the relapse of a known ANCA-associated vasculitis, in which the decision to start an induction regimen with rituximab has been taken, will be included. Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | blood specimen | blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment |
Timeline
- Start date
- 2015-09-15
- Primary completion
- 2020-06-12
- Completion
- 2020-06-12
- First posted
- 2015-06-18
- Last updated
- 2020-11-16
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02474888. Inclusion in this directory is not an endorsement.